Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718423 | 0.87 | KCNH2 (0.46) | KCNH2CYP3A4ADAM17MAPK1CYP2C9 | |
| SCHEMBL4719569 | 0.87 | KCNH2 (0.44) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL4715688 | 0.81 | KCNH2 (0.42) | KCNH2CYP3A4ADAM17CYP2C9CYP2C19 | |
| SCHEMBL4718375 | 0.77 | KCNH2 (0.42) | KCNH2CYP3A4ADAM17CYP2C9CYP2C19 | |
| SCHEMBL4719519 | 0.77 | KCNH2 (0.42) | KCNH2CYP3A4ADAM17CYP2C9CYP2C19 | |
| SCHEMBL509724 | 0.74 | KCNH2 (0.53) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL508346 | 0.74 | KCNH2 (0.54) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL10250900 | 0.73 | KCNH2 (0.78) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL509996 | 0.72 | KCNH2 (0.50) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL5226802 | 0.72 | KCNH2 (0.50) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551828-B1 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-6933312-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040133002-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133002-A1 | Pyrazole derivatives | REV1, RRS1, CYP2F1 | KCNH2 3181/4885CYP3A4 35/4885ADAM17 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.